|
PF-219,061 is a drug developed by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor.〔Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S. Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. ''Bioorganic and Medicinal Chemistry Letters''. 2007 Dec 15;17(24):6691-6. PMID 17976986〕〔Brioni JD, Moreland RB. Dopamine D4 receptors and the regulation of penile erection. ''Drug Discovery Today: Therapeutic Strategies''. 2006;3(4):599-604. 〕 It is under development as a potential medication for the treatment of female sexual dysfunction.〔(Van Der Graaf et al. SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION. WIPO Patent WO/2003/051370, granted to Pfizer ).〕〔Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I. Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. ''Xenobiotica''. 2009 Jul;39(7):523-33. PMID 19480558〕 ==See also== * ABT-670 * ABT-724 * Cabergoline * Bremelanotide * Flibanserin * Intrinsa * Melanotan II * OSU-6162 * PF-592,379 * Pramipexole * Tibolone * UK-414,495 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「PF-219,061」の詳細全文を読む スポンサード リンク
|